🇺🇸 FDA
Patent

US 12180277

LILRB4-binding antibody and methods of use thereof

granted A61KA61K2039/505A61K39/00

Quick answer

US patent 12180277 (LILRB4-binding antibody and methods of use thereof) held by The Board of Regents of the University of Texas System expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K39/00, A61K45/06, A61P